Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 99

1.

MHC Class II Antigen Presentation by the Intestinal Epithelium Initiates Graft-versus-Host Disease and Is Influenced by the Microbiota.

Koyama M, Mukhopadhyay P, Schuster IS, Henden AS, Hülsdünker J, Varelias A, Vetizou M, Kuns RD, Robb RJ, Zhang P, Blazar BR, Thomas R, Begun J, Waddell N, Trinchieri G, Zeiser R, Clouston AD, Degli-Esposti MA, Hill GR.

Immunity. 2019 Sep 18. pii: S1074-7613(19)30362-0. doi: 10.1016/j.immuni.2019.08.011. [Epub ahead of print]

PMID:
31542340
2.

Therapeutic blockade of activin-A improves NK cell function and antitumor immunity.

Rautela J, Dagley LF, de Oliveira CC, Schuster IS, Hediyeh-Zadeh S, Delconte RB, Cursons J, Hennessy R, Hutchinson DS, Harrison C, Kita B, Vivier E, Webb AI, Degli-Esposti MA, Davis MJ, Huntington ND, Souza-Fonseca-Guimaraes F.

Sci Signal. 2019 Aug 27;12(596). pii: eaat7527. doi: 10.1126/scisignal.aat7527.

PMID:
31455725
3.

Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment.

Zemek RM, De Jong E, Chin WL, Schuster IS, Fear VS, Casey TH, Forbes C, Dart SJ, Leslie C, Zaitouny A, Small M, Boon L, Forrest ARR, Muiri DO, Degli-Esposti MA, Millward MJ, Nowak AK, Lassmann T, Bosco A, Lake RA, Lesterhuis WJ.

Sci Transl Med. 2019 Jul 17;11(501). pii: eaav7816. doi: 10.1126/scitranslmed.aav7816.

PMID:
31316010
4.

The Avidity Game: Selecting Natural-Born Killers.

Andoniou CE, Schuster IS, Degli-Esposti MA.

Immunity. 2019 Jun 18;50(6):1337-1339. doi: 10.1016/j.immuni.2019.05.018.

PMID:
31216454
5.

Three-Year Follow-Up of Phase 1 and 2a rAAV.sFLT-1 Subretinal Gene Therapy Trials for Exudative Age-Related Macular Degeneration.

Rakoczy EP, Magno AL, Lai CM, Pierce CM, Degli-Esposti MA, Blumenkranz MS, Constable IJ.

Am J Ophthalmol. 2019 Aug;204:113-123. doi: 10.1016/j.ajo.2019.03.006. Epub 2019 Mar 13.

PMID:
30878487
6.

Strain-specific antibody therapy prevents cytomegalovirus reactivation after transplantation.

Martins JP, Andoniou CE, Fleming P, Kuns RD, Schuster IS, Voigt V, Daly S, Varelias A, Tey SK, Degli-Esposti MA, Hill GR.

Science. 2019 Jan 18;363(6424):288-293. doi: 10.1126/science.aat0066.

PMID:
30655443
7.

Cytomegalovirus establishes a latent reservoir and triggers long-lasting inflammation in the eye.

Voigt V, Andoniou CE, Schuster IS, Oszmiana A, Ong ML, Fleming P, Forrester JV, Degli-Esposti MA.

PLoS Pathog. 2018 May 31;14(5):e1007040. doi: 10.1371/journal.ppat.1007040. eCollection 2018 May.

8.

The Murine Natural Cytotoxic Receptor NKp46/NCR1 Controls TRAIL Protein Expression in NK Cells and ILC1s.

Sheppard S, Schuster IS, Andoniou CE, Cocita C, Adejumo T, Kung SKP, Sun JC, Degli-Esposti MA, Guerra N.

Cell Rep. 2018 Mar 27;22(13):3385-3392. doi: 10.1016/j.celrep.2018.03.023.

9.

Flt-3L Expansion of Recipient CD8α+ Dendritic Cells Deletes Alloreactive Donor T Cells and Represents an Alternative to Posttransplant Cyclophosphamide for the Prevention of GVHD.

Markey KA, Kuns RD, Browne DJ, Gartlan KH, Robb RJ, Martins JP, Henden AS, Minnie SA, Cheong M, Koyama M, Smyth MJ, Steptoe RJ, Belz GT, Brocker T, Degli-Esposti MA, Lane SW, Hill GR.

Clin Cancer Res. 2018 Apr 1;24(7):1604-1616. doi: 10.1158/1078-0432.CCR-17-2148. Epub 2018 Jan 24.

10.

A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment.

Young A, Ngiow SF, Gao Y, Patch AM, Barkauskas DS, Messaoudene M, Lin G, Coudert JD, Stannard KA, Zitvogel L, Degli-Esposti MA, Vivier E, Waddell N, Linden J, Huntington ND, Souza-Fonseca-Guimaraes F, Smyth MJ.

Cancer Res. 2018 Feb 15;78(4):1003-1016. doi: 10.1158/0008-5472.CAN-17-2826. Epub 2017 Dec 11.

11.

Ocular antigen does not cause disease unless presented in the context of inflammation.

Voigt V, Wikstrom ME, Kezic JM, Schuster IS, Fleming P, Makinen K, Daley SR, Andoniou CE, Degli-Esposti MA, Forrester JV.

Sci Rep. 2017 Oct 27;7(1):14226. doi: 10.1038/s41598-017-14618-z.

12.

ILC1 Confer Early Host Protection at Initial Sites of Viral Infection.

Weizman OE, Adams NM, Schuster IS, Krishna C, Pritykin Y, Lau C, Degli-Esposti MA, Leslie CS, Sun JC, O'Sullivan TE.

Cell. 2017 Nov 2;171(4):795-808.e12. doi: 10.1016/j.cell.2017.09.052. Epub 2017 Oct 19.

13.

Eomesodermin promotes the development of type 1 regulatory T (TR1) cells.

Zhang P, Lee JS, Gartlan KH, Schuster IS, Comerford I, Varelias A, Ullah MA, Vuckovic S, Koyama M, Kuns RD, Locke KR, Beckett KJ, Olver SD, Samson LD, Montes de Oca M, de Labastida Rivera F, Clouston AD, Belz GT, Blazar BR, MacDonald KP, McColl SR, Thomas R, Engwerda CR, Degli-Esposti MA, Kallies A, Tey SK, Hill GR.

Sci Immunol. 2017 Apr 7;2(10). pii: eaah7152. doi: 10.1126/sciimmunol.aah7152.

14.

Gene Therapy in Neovascular Age-related Macular Degeneration: Three-Year Follow-up of a Phase 1 Randomized Dose Escalation Trial.

Constable IJ, Lai CM, Magno AL, French MA, Barone SB, Schwartz SD, Blumenkranz MS, Degli-Esposti MA, Rakoczy EP.

Am J Ophthalmol. 2017 May;177:150-158. doi: 10.1016/j.ajo.2017.02.018. Epub 2017 Feb 27.

PMID:
28245970
15.

GVHD prevents NK-cell-dependent leukemia and virus-specific innate immunity.

Bunting MD, Varelias A, Souza-Fonseca-Guimaraes F, Schuster IS, Lineburg KE, Kuns RD, Fleming P, Locke KR, Huntington ND, Blazar BR, Lane SW, Tey SK, MacDonald KP, Smyth MJ, Degli-Esposti MA, Hill GR.

Blood. 2017 Feb 2;129(5):630-642. doi: 10.1182/blood-2016-08-734020. Epub 2016 Dec 7.

16.

Phase 2a Randomized Clinical Trial: Safety and Post Hoc Analysis of Subretinal rAAV.sFLT-1 for Wet Age-related Macular Degeneration.

Constable IJ, Pierce CM, Lai CM, Magno AL, Degli-Esposti MA, French MA, McAllister IL, Butler S, Barone SB, Schwartz SD, Blumenkranz MS, Rakoczy EP.

EBioMedicine. 2016 Dec;14:168-175. doi: 10.1016/j.ebiom.2016.11.016. Epub 2016 Nov 10.

17.

"Natural Regulators": NK Cells as Modulators of T Cell Immunity.

Schuster IS, Coudert JD, Andoniou CE, Degli-Esposti MA.

Front Immunol. 2016 Jun 14;7:235. doi: 10.3389/fimmu.2016.00235. eCollection 2016. Review.

18.

Ly49C Impairs NK Cell Memory in Mouse Cytomegalovirus Infection.

Forbes CA, Scalzo AA, Degli-Esposti MA, Coudert JD.

J Immunol. 2016 Jul 1;197(1):128-40. doi: 10.4049/jimmunol.1600199. Epub 2016 May 27.

19.

CIS is a potent checkpoint in NK cell-mediated tumor immunity.

Delconte RB, Kolesnik TB, Dagley LF, Rautela J, Shi W, Putz EM, Stannard K, Zhang JG, Teh C, Firth M, Ushiki T, Andoniou CE, Degli-Esposti MA, Sharp PP, Sanvitale CE, Infusini G, Liau NP, Linossi EM, Burns CJ, Carotta S, Gray DH, Seillet C, Hutchinson DS, Belz GT, Webb AI, Alexander WS, Li SS, Bullock AN, Babon JJ, Smyth MJ, Nicholson SE, Huntington ND.

Nat Immunol. 2016 Jul;17(7):816-24. doi: 10.1038/ni.3470. Epub 2016 May 23.

PMID:
27213690
20.

Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial.

Rakoczy EP, Lai CM, Magno AL, Wikstrom ME, French MA, Pierce CM, Schwartz SD, Blumenkranz MS, Chalberg TW, Degli-Esposti MA, Constable IJ.

Lancet. 2015 Dec 12;386(10011):2395-403. doi: 10.1016/S0140-6736(15)00345-1. Epub 2015 Sep 30.

PMID:
26431823
21.

Kupffer cell-monocyte communication is essential for initiating murine liver progenitor cell-mediated liver regeneration.

Elsegood CL, Chan CW, Degli-Esposti MA, Wikstrom ME, Domenichini A, Lazarus K, van Rooijen N, Ganss R, Olynyk JK, Yeoh GC.

Hepatology. 2015 Oct;62(4):1272-84. doi: 10.1002/hep.27977. Epub 2015 Jul 31.

PMID:
26173184
22.

Acute GVHD results in a severe DC defect that prevents T-cell priming and leads to fulminant cytomegalovirus disease in mice.

Wikstrom ME, Fleming P, Kuns RD, Schuster IS, Voigt V, Miller G, Clouston AD, Tey SK, Andoniou CE, Hill GR, Degli-Esposti MA.

Blood. 2015 Sep 17;126(12):1503-14. doi: 10.1182/blood-2015-01-622837. Epub 2015 Jun 30.

PMID:
26130706
23.

Deficient NLRP3 and AIM2 Inflammasome Function in Autoimmune NZB Mice.

Sester DP, Sagulenko V, Thygesen SJ, Cridland JA, Loi YS, Cridland SO, Masters SL, Genske U, Hornung V, Andoniou CE, Sweet MJ, Degli-Esposti MA, Schroder K, Stacey KJ.

J Immunol. 2015 Aug 1;195(3):1233-41. doi: 10.4049/jimmunol.1402859. Epub 2015 Jun 26.

24.

NK cells require IL-28R for optimal in vivo activity.

Souza-Fonseca-Guimaraes F, Young A, Mittal D, Martinet L, Bruedigam C, Takeda K, Andoniou CE, Degli-Esposti MA, Hill GR, Smyth MJ.

Proc Natl Acad Sci U S A. 2015 May 5;112(18):E2376-84. doi: 10.1073/pnas.1424241112. Epub 2015 Apr 21.

25.

High Chlamydia Burden Promotes Tumor Necrosis Factor-Dependent Reactive Arthritis in SKG Mice.

Baillet AC, Rehaume LM, Benham H, O'Meara CP, Armitage CW, Ruscher R, Brizard G, Harvie MC, Velasco J, Hansbro PM, Forrester JV, Degli-Esposti MA, Beagley KW, Thomas R.

Arthritis Rheumatol. 2015 Jun;67(6):1535-47. doi: 10.1002/art.39041.

26.

A natural genetic variant of granzyme B confers lethality to a common viral infection.

Andoniou CE, Sutton VR, Wikstrom ME, Fleming P, Thia KY, Matthews AY, Kaiserman D, Schuster IS, Coudert JD, Eldi P, Chaudhri G, Karupiah G, Bird PI, Trapani JA, Degli-Esposti MA.

PLoS Pathog. 2014 Dec 11;10(12):e1004526. doi: 10.1371/journal.ppat.1004526. eCollection 2014 Dec.

27.

TRAIL+ NK cells control CD4+ T cell responses during chronic viral infection to limit autoimmunity.

Schuster IS, Wikstrom ME, Brizard G, Coudert JD, Estcourt MJ, Manzur M, O'Reilly LA, Smyth MJ, Trapani JA, Hill GR, Andoniou CE, Degli-Esposti MA.

Immunity. 2014 Oct 16;41(4):646-56. doi: 10.1016/j.immuni.2014.09.013.

28.

Peripheral natural killer cell maturation depends on the transcription factor Aiolos.

Holmes ML, Huntington ND, Thong RP, Brady J, Hayakawa Y, Andoniou CE, Fleming P, Shi W, Smyth GK, Degli-Esposti MA, Belz GT, Kallies A, Carotta S, Smyth MJ, Nutt SL.

EMBO J. 2014 Nov 18;33(22):2721-34. doi: 10.15252/embj.201487900. Epub 2014 Oct 15.

29.

Ly49C-dependent control of MCMV Infection by NK cells is cis-regulated by MHC Class I molecules.

Forbes CA, Scalzo AA, Degli-Esposti MA, Coudert JD.

PLoS Pathog. 2014 May 29;10(5):e1004161. doi: 10.1371/journal.ppat.1004161. eCollection 2014 May.

30.

The early monocytic response to cytomegalovirus infection is MyD88 dependent but occurs independently of common inflammatory cytokine signals.

Wikstrom ME, Khong A, Fleming P, Kuns R, Hertzog PJ, Frazer IH, Andoniou CE, Hill GR, Degli-Esposti MA.

Eur J Immunol. 2014 Feb;44(2):409-19. doi: 10.1002/eji.201243109. Epub 2013 Dec 16.

31.

CpG pretreatment enhances antiviral T-cell immunity against cytomegalovirus.

Ong ML, Wikstrom ME, Fleming P, Estcourt MJ, Hertzog PJ, Hill GR, Andoniou CE, Degli-Esposti MA.

Blood. 2013 Jul 4;122(1):55-60. doi: 10.1182/blood-2012-12-471227. Epub 2013 May 14.

32.

Targeting of a natural killer cell receptor family by a viral immunoevasin.

Berry R, Ng N, Saunders PM, Vivian JP, Lin J, Deuss FA, Corbett AJ, Forbes CA, Widjaja JM, Sullivan LC, McAlister AD, Perugini MA, Call MJ, Scalzo AA, Degli-Esposti MA, Coudert JD, Beddoe T, Brooks AG, Rossjohn J.

Nat Immunol. 2013 Jul;14(7):699-705. doi: 10.1038/ni.2605. Epub 2013 May 12.

PMID:
23666294
33.

A chemokine-like viral protein enhances alpha interferon production by plasmacytoid dendritic cells but delays CD8+ T cell activation and impairs viral clearance.

Wikstrom ME, Fleming P, Comerford I, McColl SR, Andoniou CE, Degli-Esposti MA.

J Virol. 2013 Jul;87(14):7911-20. doi: 10.1128/JVI.00187-13. Epub 2013 May 8.

34.

Cell-based therapies for ocular inflammation.

Forrester JV, Steptoe RJ, Klaska IP, Martin-Granados C, Dua HS, Degli-Esposti MA, Wikstrom ME.

Prog Retin Eye Res. 2013 Jul;35:82-101. doi: 10.1016/j.preteyeres.2013.02.002. Epub 2013 Mar 29. Review.

PMID:
23542232
35.

MCMV-mediated inhibition of the pro-apoptotic Bak protein is required for optimal in vivo replication.

Fleming P, Kvansakul M, Voigt V, Kile BT, Kluck RM, Huang DC, Degli-Esposti MA, Andoniou CE.

PLoS Pathog. 2013 Feb;9(2):e1003192. doi: 10.1371/journal.ppat.1003192. Epub 2013 Feb 28.

36.

Interferon γ-dependent migration of microglial cells in the retina after systemic cytomegalovirus infection.

Zinkernagel MS, Chinnery HR, Ong ML, Petitjean C, Voigt V, McLenachan S, McMenamin PG, Hill GR, Forrester JV, Wikstrom ME, Degli-Esposti MA.

Am J Pathol. 2013 Mar;182(3):875-85. doi: 10.1016/j.ajpath.2012.11.031. Epub 2013 Jan 10.

37.

β-glucan triggers spondylarthritis and Crohn's disease-like ileitis in SKG mice.

Ruutu M, Thomas G, Steck R, Degli-Esposti MA, Zinkernagel MS, Alexander K, Velasco J, Strutton G, Tran A, Benham H, Rehaume L, Wilson RJ, Kikly K, Davies J, Pettit AR, Brown MA, McGuckin MA, Thomas R.

Arthritis Rheum. 2012 Jul;64(7):2211-22. doi: 10.1002/art.34423.

38.

TLR9 ligand CpG-ODN applied to the injured mouse cornea elicits retinal inflammation.

Chinnery HR, McLenachan S, Binz N, Sun Y, Forrester JV, Degli-Esposti MA, Pearlman E, McMenamin PG.

Am J Pathol. 2012 Jan;180(1):209-20. doi: 10.1016/j.ajpath.2011.09.041. Epub 2011 Nov 12.

39.

Preclinical safety evaluation of subretinal AAV2.sFlt-1 in non-human primates.

Lai CM, Estcourt MJ, Himbeck RP, Lee SY, Yew-San Yeo I, Luu C, Loh BK, Lee MW, Barathi A, Villano J, Ang CL, van der Most RG, Constable IJ, Dismuke D, Samulski RJ, Degli-Esposti MA, Rakoczy EP.

Gene Ther. 2012 Oct;19(10):999-1009. doi: 10.1038/gt.2011.169. Epub 2011 Nov 10.

PMID:
22071974
40.

Kinetics of ocular and systemic antigen-specific T-cell responses elicited during murine cytomegalovirus retinitis.

Zinkernagel MS, Petitjean C, Wikstrom ME, Degli-Esposti MA.

Immunol Cell Biol. 2012 Mar;90(3):330-6. doi: 10.1038/icb.2011.43. Epub 2011 May 17.

PMID:
21577228
41.

T cell responses in experimental viral retinitis: mechanisms, peculiarities and implications for gene therapy with viral vectors.

Zinkernagel MS, McMenamin PG, Forrester JV, Degli-Esposti MA.

Prog Retin Eye Res. 2011 Jul;30(4):275-84. doi: 10.1016/j.preteyeres.2011.04.001. Epub 2011 Apr 27. Review.

PMID:
21550416
42.

Administration of alpha-galactosylceramide impairs the survival of dendritic cell subpopulations in vivo.

Simkins HM, Hyde E, Farrand KJ, Ong ML, Degli-Esposti MA, Hermans IF, Ronchese F.

J Leukoc Biol. 2011 May;89(5):753-62. doi: 10.1189/jlb.0910480. Epub 2011 Feb 4.

PMID:
21297009
43.

CD83 increases MHC II and CD86 on dendritic cells by opposing IL-10-driven MARCH1-mediated ubiquitination and degradation.

Tze LE, Horikawa K, Domaschenz H, Howard DR, Roots CM, Rigby RJ, Way DA, Ohmura-Hoshino M, Ishido S, Andoniou CE, Degli-Esposti MA, Goodnow CC.

J Exp Med. 2011 Jan 17;208(1):149-65. doi: 10.1084/jem.20092203. Epub 2011 Jan 10.

44.

Cathepsin C limits acute viral infection independently of NK cell and CD8+ T-cell cytolytic function.

Andoniou CE, Fleming P, Sutton VR, Trapani JA, Degli-Esposti MA.

Immunol Cell Biol. 2011 May;89(4):540-8. doi: 10.1038/icb.2010.115. Epub 2010 Oct 26.

PMID:
20975734
45.

Innate immunity defines the capacity of antiviral T cells to limit persistent infection.

Andrews DM, Estcourt MJ, Andoniou CE, Wikstrom ME, Khong A, Voigt V, Fleming P, Tabarias H, Hill GR, van der Most RG, Scalzo AA, Smyth MJ, Degli-Esposti MA.

J Exp Med. 2010 Jun 7;207(6):1333-43. doi: 10.1084/jem.20091193. Epub 2010 May 31.

46.

Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth.

van der Most RG, Currie AJ, Cleaver AL, Salmons J, Nowak AK, Mahendran S, Larma I, Prosser A, Robinson BW, Smyth MJ, Scalzo AA, Degli-Esposti MA, Lake RA.

PLoS One. 2009 Sep 10;4(9):e6982. doi: 10.1371/journal.pone.0006982.

47.

In vivo imaging of ocular MCMV infection.

Zinkernagel MS, Petitjean C, Fleming P, Chinnery HR, Constable IJ, McMenamin PG, Degli-Esposti MA.

Invest Ophthalmol Vis Sci. 2010 Jan;51(1):369-74. doi: 10.1167/iovs.09-4083. Epub 2009 Aug 13.

PMID:
19684003
48.

The roles of interferon-gamma and perforin in antiviral immunity in mice that differ in genetically determined NK-cell-mediated antiviral activity.

Sumaria N, van Dommelen SL, Andoniou CE, Smyth MJ, Scalzo AA, Degli-Esposti MA.

Immunol Cell Biol. 2009 Oct;87(7):559-66. doi: 10.1038/icb.2009.41. Epub 2009 Jun 30.

PMID:
19564888
49.

rAAV.sFlt-1 gene therapy achieves lasting reversal of retinal neovascularization in the absence of a strong immune response to the viral vector.

Lai CM, Estcourt MJ, Wikstrom M, Himbeck RP, Barnett NL, Brankov M, Tee LB, Dunlop SA, Degli-Esposti MA, Rakoczy EP.

Invest Ophthalmol Vis Sci. 2009 Sep;50(9):4279-87. doi: 10.1167/iovs.08-3253. Epub 2009 Apr 8.

PMID:
19357358
50.

Graft-versus-host disease prevents the maturation of plasmacytoid dendritic cells.

Banovic T, Markey KA, Kuns RD, Olver SD, Raffelt NC, Don AL, Degli-Esposti MA, Engwerda CR, MacDonald KP, Hill GR.

J Immunol. 2009 Jan 15;182(2):912-20. Erratum in: J Immunol. 2009 Mar 1;182(5):3327.

Supplemental Content

Loading ...
Support Center